MAC News 65.58 Macerich Company (MAC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Macerich Company (MAC) 65.58 $MAC

Macerich Up 10.6% Since SmarTrend Uptrend Call (MAC)
Comtex SmarTrend(R) - Wed Apr 16, 9:57AM CDT
SmarTrend identified an Uptrend for Macerich (NYSE:MAC) on February 7th, 2014 at $58.90. In approximately 2 months, Macerich has returned 10.64% as of today's recent price of $65.16.

Scheduled Earnings Releases, Stock Price Movement, and New Flagship Stores' Opening - Analyst Notes on HCP, Public Storage, Macerich, AIMCO, and Extra Space Storage
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding HCP, Inc. (NYSE: HCP), Public Storage (NYSE: PSA), Macerich Co. (NYSE: MAC), Apartment Investment and Management Co. (NYSE: AIV), and Extra Space Storage Inc. (NYSE: EXR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1041-100free

Stock Updates, Asset Sales, Upcoming Investors Conferences, and Mall Redevelopments - Analyst Notes on Federal Realty, DDR, HTGC, Macerich, and CBL
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Federal Realty Investment Trust (NYSE: FRT), DDR Corp. (NYSE: DDR), Hercules Technology Growth Capital, Inc. (NYSE: HTGC), Macerich Co. (NYSE: MAC), and CBL & Associates Properties Inc. (NYSE: CBL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Balanced View on Macerich - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:00AM CDT
On Mar 27, 2014, we issued an updated research report on retail real estate investment trust (REIT), The Macerich Company.

Property Prices Are Improving: Is It Time to Buy REITs?
Louie Grint, The Motley Fool - Motley Fool - Fri Mar 28, 6:00AM CDT
Source: Ben Schuman. Property prices are finally on the recovery path. In fact, if you take a look at the S&P Case-Shiller 20 cities index, you'll notice that seasonality-adjusted prices were up 21% in the beginning of this year compared to its...

Simon Property Launches Simon Venture Group - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 10:00AM CDT
In order to leverage on the growing opportunities of technology application in the retail sector, Simon Property launched Simon Venture Group for making investments in retail innovation.

Macerich Schedules First Quarter 2014 Earnings Release And Conference Call
PR Newswire - Thu Mar 20, 3:15PM CDT
SANTA MONICA, Calif., March 20, 2014 /PRNewswire/--

3 Buy-Rated Dividend Stocks Taking The Lead: MO, PSEC, MAC
at The Street - Wed Mar 19, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet

3 Buy-Rated Dividend Stocks Taking The Lead: AEP, MAC, LPT
at The Street - Mon Mar 10, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet

Zacks Industry Outlook Highlights: CBRE Group, Simon Property Group, Macerich and General Growth Properties
PR Newswire - Wed Feb 26, 8:30AM CST
Today, Zacks Equity Research discusses the Real Estate Investment Trust (REIT), including CBRE Group, Inc. (NYSE:CBG-Free Report), Simon Property Group Inc. (NYSE:SPG-Free Report), Macerich Company (NYSE:MAC-Free Report) and General Growth Properties, Inc. (NYSE:GGP-Free Report).

Macerich To Present At Citi 2014 Global Property CEO Conference
PR Newswire - Wed Feb 26, 5:00AM CST
Macerich® (NYSE: MAC), today announced that Art Coppola, CEO and Chairman of the Board of Directors, Ed Coppola, President and Tom O'Hern, Senior Executive Vice President and Chief Financial Officer will participate in the Citi 2014 Global Property CEO Conference in Hollywood, Florida.

REIT Industry Review & Stock Picks - Feb 2014 - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 2:39AM CST
REIT Industry Review & Stock Picks - Feb 2014 - Industry Outlook

REIT Industry Review & Stock Picks - Feb 2014 - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 2:39AM CST
REIT Industry Review & Stock Picks - Feb 2014 - Zacks Analyst Interviews

Deliv Welcomes Strategic Investments from Mall Operators Simon Property Group, General Growth Properties, Macerich and Westfield
PR Newswire - Mon Feb 24, 9:19AM CST
Deliv today announced it closed a $4.5 million round of investment from mall operators Simon Property Group, General Growth Properties, Macerich and Westfield, as well as existing investors Upfront Ventures, RPM Ventures and others. This funding follows a $7.85 million round completed in the summer of 2013.

Vornado to Sell Its Last Mall in Long Island - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 2:30PM CST
On Feb 14, Real estate investment trust (REIT) Vornado Realty Trust declared that it has inked a deal to sell Broadway Mall for $94 million.

Macerich Beats on Q4 FFO & Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:50AM CST
Macerich's fourth-quarter 2013 AFFO per share surpassed both the Zacks Consensus Estimate by a penny and year ago figure.

Macerich Announces Adjusted Funds From Operations Per Share Increases 11% For 2013
PR Newswire - Tue Feb 04, 4:51PM CST
The Macerich Company (NYSE Symbol: MAC) today announced results of operations for the quarter ended December 31, 2013 which included adjusted funds from operations ("AFFO" diluted of $140.6 million or $.94 per share-diluted compared to $132.6 million or $.90 per share-diluted for the quarter ended December 31, 2012. Net income attributable to the Company was $144.9 million or $1.03 per share-diluted for the quarter ended December 31, 2013 compared to net income attributable to the Company for the quarter ended December 31, 2012 of $174.3 million or $1.27 per share-diluted. AFFO diluted for the year ended December 31, 2013 was $527.6 million or $3.53 per share-diluted compared to $460.9 million or $3.18 per share-diluted for the year ended December 31, 2012. Net income attributable to the Company was $420.1 million or $3.00 per share-diluted for the year ended December 31, 2013 compared to net income attributable to the Company for the year ended December 31, 2012 of $337.4 million or $2.51 per share-diluted. A description and reconciliation of funds from operations ("FFO" per share-diluted and AFFO per share-diluted to EPS-diluted is included in the financial tables accompanying this press release.

Simon Property Beats on Q4 FFO, Hikes Div - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 9:11AM CST
Simon Property reported fourth-quarter 2013 FFO of $2.47 per share that came 4 cents ahead of the Zacks Consensus Estimate. It also hiked its quarterly dividend payout by nearly 4.2%.

Macerich Declares The Quarterly Dividend On Its Common Shares
PR Newswire - Thu Jan 30, 12:39PM CST
The Board of Directors of The Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $.62 per share of common stock. The dividend is payable on March 7, 2014 to stockholders of record at the close of business on February 21, 2014.

What To Buy: Top 3 Buy-Rated Dividend Stocks: MAA, MAC, APU
at The Street - Thu Jan 30, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading